Back to Journals » Journal of Asthma and Allergy » Volume 13

Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs

Authors Llanos JP, Ortega H, Bogart M, Packnett ER, Manjelievskaia J, Bell CF, Hahn B

Received 30 October 2019

Accepted for publication 7 January 2020

Published 29 January 2020 Volume 2020:13 Pages 77—87

DOI https://doi.org/10.2147/JAA.S236609

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Luis Garcia-Marcos


Jean-Pierre Llanos,1 Hector Ortega,1 Michael Bogart,2 Elizabeth R Packnett,3 Janna Manjelievskaia,3 Christopher F Bell,2 Beth Hahn2

1Respiratory, US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2US Value Evidence and Outcomes, US Medical Affairs, GSK, Research Triangle Park, NC, USA; 3Life Sciences, IBM Watson Health, Bethesda, MD, USA

Correspondence: Beth Hahn
US Value Evidence and Outcomes, US Medical Affairs, GSK, 5 Moore Drive, Research Triangle Park, NC 27709-3398, USA
Tel +1 919-274-0660
Email Beth.a.hahn@gsk.com

Rationale: Results from clinical trials in patients with severe eosinophilic asthma have demonstrated that mepolizumab is well tolerated and is associated with improved asthma control as evidenced by reductions in both exacerbations and maintenance oral corticosteroid use, and improvements in lung function, asthma control, and quality of life. However, real-world data are lacking on the impact of mepolizumab treatment.
Objective: To assess the effect of mepolizumab treatment on the rate of asthma exacerbations and asthma exacerbation-related costs in a real-world setting.
Methods: This retrospective cohort study (GSK ID: 209017; HO-18-19168) analyzed data from patients with severe asthma ≥ 12 years of age at mepolizumab treatment initiation (index date) with ≥ 12 months pre- (baseline) and post-index (follow-up) data from a commercial claims database (patients were identified from November 1, 2015 to March 31, 2017). Asthma exacerbations (primary objective) and asthma exacerbation-related costs (secondary objective) in the baseline and follow-up periods were compared. Other analyses included the number of mepolizumab administrations and the use of concomitant asthma medications.
Results: Data were analyzed from 346 patients. Mepolizumab significantly reduced the proportion of patients with any exacerbation and exacerbations requiring hospitalization, compared with baseline. Significant reductions in the rate of all exacerbations of 38.4% (from 2.68 to 1.65 events/patient/year; P< 0.001) and of exacerbations requiring hospitalization of 72.7% (from 0.11 to 0.03 events/patient/year; P=0.004) were observed, compared with baseline. Mean total asthma exacerbation-related costs (excluding mepolizumab acquisition and administrative costs) per person were significantly lower during follow-up compared with baseline (P< 0.05) and the use of asthma medications, including oral and inhaled corticosteroids, was also lower.
Conclusion: This study confirms the clinical benefit observed in previous mepolizumab clinical trials and demonstrates that mepolizumab is effective in a real-world setting.

Keywords: asthma exacerbation, mepolizumab, cost, real world, effectiveness

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]